Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
Key facts
- Where
- Padova, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06753136, who can take part
Where in Italy
- Istituto Oncologico VenetoPadova, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Istituto Oncologico Veneto IRCCS
- Trial code
- NCT06753136
- Record updated
- 13 April 2026
- Original description
This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneous metastases of different tumor histotypes.Read full original descriptionShow less
Treatment of Visceral Localizations With Electrochemotherapy in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype: Monocenter, Single Arm, Clinical Investigation
This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneous metastases of different tumor histotypes.
Although still limited, the various experiences in the treatment of visceral localizations, particularly in liver metastases from colorectal cancer are promising and show that electrochemotherapy is a safe treatment, even in the case of lesions near large vessels or nerves. The investigators therefore propose a clinical investigation with a Medical Device according to EU Regulation 745/2017, using electrochemotherapy (Cliniporator) with bleomycin for the treatment of visceral, primary or secondary, unresectable localizations, with percutaneous or intraoperative technique (laparoscopic or laparotomy), as needed.
Inclusion: Male/Female ≥ 18 years; Ability to understand the proposed treatment and express an informed acceptance by signing the informed consent; Diagnosis of primary and/or secondary visceral localizations of any histotype; Patients who are not eligible for standard curative procedures.
Exclusion: Concomitant presence of brain, lung, bone metastases; Bleomycin allergy; Acute lung infections; Absolute contraindications to invasive procedures; Uncorrectable coagulation changes; Absolute contraindications to taking Bleomycin; Poor respiratory function or pulmonary fibrosis; Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study.